A First-in-human Phase 1 Dose-escalation Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of KST-6051 in Patients With Advanced or Metastatic Solid Tumors With a KRAS Mutation

This early-stage study is testing a new medication called KST-6051 to see if it is safe for adults with advanced solid tumor cancers. It focuses on cancers that have a specific genetic change known as a KRAS mutation, such as certain lung, pancreatic, and colorectal cancers.

You may be able to join if you are 18 or older, have an advanced solid tumor with a KRAS mutation, and your cancer has progressed or standard treatments did not work for you. You must also be able to swallow pills and not have received prior treatments targeting RAS or KRAS.

Participants will take the investigational study medication, KST-6051, by mouth as a pill. Doctors will carefully monitor your health, check for side effects, and see how well your body responds to the treatment.

This study is currently recruiting participants at locations in Los Angeles, California, and Sarasota and Tampa, Florida. You can talk to your care team to see if one of these locations is right for you.